Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology · 2015

Cited by 949 works. doi:10.1016/s1470-2045(15)70127-0

Authors

References